<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> is characterized by arterial and <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> and is associated with the presence of circulating <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0004420'>Arterial thrombosis</z:hpo> can result in <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo>, which may potentially lead to end-stage <z:hpo ids='HP_0001635'>heart failure</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Here we report our anticoagulation protocol for patients with <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> that undergo axial-flow left ventricle assist devices (HeartMate II; Thoratec, Pleasanton, CA) implantation </plain></SENT>
</text></document>